A Tyrosine Kinase Inhibitor that Successfully Treats nAMD
03/03/22 • 17 min
We discuss the DAVIO trial of EYP-1901 with Dr. Jay S. Duker, Chief Operating Officer of Eyepoint Pharmaceuticals.
We discuss the DAVIO trial of EYP-1901 with Dr. Jay S. Duker, Chief Operating Officer of Eyepoint Pharmaceuticals.
Previous Episode
Late Breaking News on Kodiak Dazzle Trial
We review the results of the KS-301 wet macular degeneration trial with Dr. Carl Regillo,
Chief of the Retina Service at Wills Eye Hospital
Next Episode
The Paladin Study of the Fluocinolone Implant Treating Diabetic Macular Edema
The fluocinolone implant at 3 years is a useful modality for treating diabetic macular edema. Discussion with Dr. Michael Singer, Adjunct Professor University of Texas at San Antonio.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/retina-synthesis-352057/a-tyrosine-kinase-inhibitor-that-successfully-treats-namd-50910547"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to a tyrosine kinase inhibitor that successfully treats namd on goodpods" style="width: 225px" /> </a>
Copy